Nice approves mavacamten, used to treat obstructive hypertrophic cardiomyopathy, in draft guidance to NHS
A first-of-its-kind treatment targeting a chronic heart disease could offer a “greater hope” to thousands of people living with the condition.
The National Institute for Health and Care Excellence (Nice) has approved the use of mavacamten in draft guidance to the NHS. It would be used to treat those with obstructive hypertrophic cardiomyopathy (HCM), with about 7,000 people expected to benefit.
About Author
More Stories
NHS to begin world-first trial of AI tool to identify type 2 diabetes risk
Middle children are more cooperative than their siblings, study suggests
Esports are booming in Africa – but can its infrastructure keep pace?